DXCM
ACCE-researchedDexCom Inc. Common Stock
Healthcare · Medical Devices · NASDAQ · United States
$89.35+1.61%
Market cap $33.7BNext earnings 2026-10-29Updated Sep 19, 2026
FAIR VALUE · CONSENSUS
$89.35+0.0%
confidence-weighted across 3 of 6 models
Now $89.35
$89.35
$28.13$120.83
TrimSilver73
Price vs fair value
22.2% above
-18.2% to fair value
ACCE score
76
out of 100
Analysts
89% buy
27 covering
P/E
35.3x
forward 28.7x
1-year return
+17.9%
Dividend yield
0.00%
Unlock the ACCE read
INVESTOROverview
Reports in 38 days, last quarter beat by 0.1%.
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
Price
+28.5% · 1Y
Valuation
INVESTORFull valuation engine INVESTOR FEATURE
Six independent models converge on one confidence-weighted fair value, with full methodology and editable assumptions.
- +All six models: DCF, P/E and EV/EBITDA comps, Graham, dividend discount, residual income
- +Scenario bands, sensitivity tornado, and the 5-year historical valuation range
- +Editable DCF workbench with saved scenarios
Quality
INVESTORQuality and conviction INVESTOR FEATURE
The full quality picture: conviction breakdown, earnings quality, score history, and backtested returns.
- +Conviction score breakdown and earnings-quality grade
- +Growth / value / quality / momentum component scores
- +90-day score history and score-threshold backtests
Analysts
Wall Street consensus
Bullish89% buy · 27 covering analysts
● Strong buy 21● Buy 3● Hold 3● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
- +Price-target low / average / high vs the current price, with implied upside
- +Forward revenue and EPS consensus by fiscal year
- +ACCE fair-value models lined up against the Street
Smart Money
PROSmart money tracking PRO FEATURE
Follow the institutions: 13F position changes, insider trades, and active 13D activist filings.
- +Quarter-over-quarter institutional position changes
- +Recent open-market insider transactions
- +Active 13D activist filings and top holders
Compare
Where it sits vs peers
This stock Peer Peer median weaker → stronger
P/Ebetter than 17% of peers
low 14.8x35.3xhigh 52.5x
ROEbetter than 100% of peers
low 9%38%high 38%
Div yieldbetter than 17% of peers
low 0.0%0.0%high 4.1%
Algorithmic peers (6)
| Ticker | Company | Mcap | P/E | ROE | D/E | Yield | Quality | |
|---|---|---|---|---|---|---|---|---|
| GEHC | GE HealthCare Technologies Inc. Common Stock | $29.0B | 14.8 | 19.4% | 0.96 | 0.2% | - | Compare |
| PHIA.AS | Koninklijke Philips | $24.2B | 18.9 | 10.2% | 0.62 | 4.0% | - | Compare |
| PHG | Koninklijke Philips N.V. NY Registry Shares | $24.1B | 18.8 | 10.2% | 0.71 | 4.1% | - | Compare |
| SHL.DE | Siemens Healthineers | $48.4B | 19.2 | 12.2% | 0.61 | 2.6% | - | Compare |
| EW | Edwards Lifesciences Corporation Common Stock | $50.9B | 52.5 | 9.2% | 0.06 | 0.0% | - | Compare |
| 4543.T | Terumo | $20.9B | 24.3 | 10.9% | 26.36 | 1.6% | - | Compare |
Sector report card
Where DXCM ranks against its sector peers on each metric.
Computing percentiles…
News and Record
Reports in 38 days, last quarter beat by 0.1%.
Press releases mentioning this company
Ask anything, Pro feature
Ask questions about this stock in plain language. Answered from company fundamentals + recent valuations.
PRO
Recent performance
1 week
+7.6%
1 month
-0.6%
3 months
+23.3%
6 months
+33.5%
YTD
+34.6%
1 year
+17.9%
SEC filings
40 filings
September 2026
Sep 16
Form 4Insider transactionPeriod 2026-09-14
Sep 16
Form 4Insider transactionPeriod 2026-09-15
Sep 14
8-KCurrent reportPeriod 2026-09-10
37 more filings + AI summaries on Investor+.INVESTOR